Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

TUPELO — For those who have tried unsuccessfully to use a CPAP machine to treat sleep apnea, the Inspire implant is a breakthrough solution. Larry Ferguson, 77, of Pontotoc, is among those whose ...

Standard treatment of this chronic ... When Lilly posted preliminary data from the sleep apnea study in April, the stock prices of companies such as Inspire Medical Systems, which makes CPAP ...

Shelby Knowles / Bloomberg via Getty Images Shares of ResMed and Inspire ... sleep apnea, and those drugs will likely be used "concomitantly with positive airway pressure (PAP) therapy," such ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

weight loss drug for “treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” In addition to the GLP-1 prescription, the FDA suggests that users reduce their ...

The FDA has approved Zepbound (tirzepatide) for treating moderate to severe obstructive sleep apnea (OSA ... airway pressure (PAP), the standard treatment for moderate to severe OSA, while ...

US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for the condition that affects millions of Americans. "This is a major step ...